Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease

Arthritis Research and Therapy

Volumn 18, Issue 1, 2016, Pages

  Volkmann, Elizabeth R ^a   Tashkin, Donald P ^a   Roth, Michael D ^a   Clements, Philip J ^a   Khanna, Dinesh ^b   Furst, Daniel E ^a   Mayes, Maureen ^c   Charles, Julio ^c   Tseng, Chi Hong ^a   Elashoff, Robert M ^d   Assassi, Shervin ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemokines; Immunosuppression; Pulmonary fibrosis; Systemic sclerosis

Indexed keywords

CARBON MONOXIDE; CHEMOKINE; CXCL4 CHEMOKINE; CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID; PLACEBO; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; IMMUNOSUPPRESSIVE AGENT; THROMBOCYTE FACTOR 4;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DOWN REGULATION; DRUG RESPONSE; FEMALE; FORCED VITAL CAPACITY; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARALLEL DESIGN; PREDICTION; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC SCLEROSIS; THORAX RADIOGRAPHY; TREATMENT DURATION; BLOOD; COMPLICATION; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; LUNG DISEASES, INTERSTITIAL; LUNG FUNCTION TEST; MIDDLE AGED;

ADULT; AGED; BIOMARKERS; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PLATELET FACTOR 4; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC;

EID: 85007484082     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-016-1203-y     Document Type: Article

References (25)

1. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69:1809-15.
2. Wells AU. Interstitial lung disease in systemic sclerosis. Press Med. 2014;43:e329-43.
3. Morgan C, Knight C, Lunt M, et al. Predictors of end stage lung disease in a cohort of patients with scleroderma. Ann Rheum Dis. 2003;62:146-50.
4. Plastiras SC, Karadimitrakis SP, Ziakas PD, et al. Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum. 2006;55:598-602.
5. Nihtyanova SI, Schreiber BE, Ong VH, et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol. 2014;66:1625-35.
6. Steen VD, Medsger Jr TA. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000;43:2437-44.
7. Goh NSL, Desai SR, Veeraraghaven S, et al. Interstitial lung disease in systemic sclerosis. A simple staging system. Am J Respir Crit Care Med. 2008;177:1248-54.
8. Moore OA, Goh N, Corte T, et al. Extent of disease on high-resolution compute tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology (Oxford). 2013;165:378-81.
9. Assassi S, Sharif R, Lasky RE, et al. GENISOS Study Group. Arthritis Res Ther. 2010;12:R166.
10. Roth MD, Tseng CH, Clements PJ, et al. Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. Arthritis Rheum. 2011;63:2797-808.
11. De Lauretis A, Sestini P, Pantelidis P, et al. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol. 2013;40:435-46.
12. Liu X, Mayes MD, Pedroza C, et al. Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis Arthritis Care Res. 2013;65:1375-80.
13. Wu M, Pedroza C, Salazar G, et al. Plasma MCP-1 and IL-10 levels predict long-term progression of interstitial lung disease in patients with early systemic sclerosis. Arthritis Rheum. 2013;65:S742.
14. Tiev KP, Hua-Huy T, Kettaneh A, et al. Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis. Eur Respir. 2011;38:1355-60.
15. Schupp J, Becker M, Günther J, et al. Serum CCL18 is predictive for lung disease progression and mortality in systemic sclerosis. Eur Respir J. 2014;43:1530-2.
16. van Bon L, Affandi AJ, Broen J, et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med. 2014;370:433-43.
17. Masi T. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheumatol. 1980;23:581-90.
18. Mahler DA, Weinberg DH, Wells CK, et al. The measurement of dyspnea. Contents, interobserver agreement and physiologic correlates of two new clinical indexes. Chest. 1984;85:751-8.
19. Tashkin DP, Roth MD, Clements PJ, et al., for the Scleroderma Lung Study II Investigators. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease: Scleroderma lung study II (SLS-II), a double-blind, parallel group, mmunomodu controlled trial. Lancet Resp Med. 2016. [Epub ahead of print]
20. Kim HJ, Li G, Gjertson D, et al. Classification of parenchymal abnormality in scleroderma lung using a novel approach to denoise images collected via a multicenter study. Acad Radiol. 2008;15:1004-16.
21. Zaldivar MM, Pauels K, von Hundelshausen P, et al. CXC chemokine ligand 4 (Cxcl4) is a platelet-derived mediator of experimental liver fibrosis. Hepatology. 2010;51:1345-53.
22. Patsouras MD, Skiara MP, Grikak EP, et al. Elevated expression of platelet-derived chemokines in patients with antiphospholipid syndrome. J Autoimmun. 2015;65:30-7.
23. van Bon L, Cossu M, Scharstuhl A, et al. Low heme oxygenase-1 levels in patients with systemic sclerosis are associated with an altered Toll-like receptor response: another role for CXCL4 Rheumatol (Oxford). 2016 [Epub ahead of print].
24. Gourh P, Arnett FC, Assassi S, et al. Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthritis Res Ther. 2009;11:R147.
25. R&D Systems: Quantikine ELISA Human CXCL4/PF4 Immunoassay. https://resources.rndsystems.com/pdfs/datasheets/dpf40.pdf (2016). Accessed 13 Sep 2016.